Who Paid My Doc
Michael Moran
Interventional Cardiology Laguna Niguel, CA Medical Doctor
NPI 1871564948 CMS profile 266775
30131 Town Center Dr Ste 211, Laguna Niguel, CA 92677
General payments
$411
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Michael Moran of Laguna Niguel, CA is reported in the CMS Open Payments database as having received $411 across 7 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 7th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $51 | 1 | |
| 2024 | General | $16 | 1 | |
| 2023 | General | $283 | 3 | |
| 2019 | General | $61 | 2 |
Beside peers
- Michael Moran
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Michael Moran were reported at $51. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Michael Moran | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $61 | $1,097 | $329–$3,048 | $163 |
| 2020 | $0 | $473 | $161–$1,480 | $114 |
| 2021 | $0 | $677 | $233–$1,827 | $132 |
| 2022 | $0 | $978 | $333–$2,724 | $149 |
| 2023 | $283 | $1,136 | $382–$2,986 | $160 |
| 2024 | $16 | $1,181 | $395–$3,326 | $164 |
| 2025 | $51 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 57 drugsPart D claims
3,326
Drug cost
$926,541
Branded share of claims
41.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 268 | $354,542 | |
| Mounjaro Tirzepatide | Brand | 81 | $104,790 | |
| Xarelto Rivaroxaban | Brand | 96 | $81,823 | |
| Entresto Sacubitril/Valsartan | Brand | 55 | $59,022 | |
| Januvia Sitagliptin Phosphate | Brand | 44 | $53,288 | |
| Jardiance Empagliflozin | Brand | 44 | $48,198 | |
| Rybelsus Semaglutide | Brand | 32 | $43,561 | |
| Repatha Sureclick Evolocumab | Brand | 43 | $41,104 | |
| Eliquis Apixaban | Brand | 37 | $31,946 | |
| Verquvo Vericiguat | Brand | 12 | $17,415 |
The 10 drugs with the highest cost, of 57 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 45 billing codesPaid by Medicare
$176,447
Medicare patients
290
Services billed
1,823
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 62% | |
| Arthritis | 39% | |
| Ischemic heart disease | 37% | |
| Atrial fibrillation | 27% | |
| Heart failure | 21% | |
| Chronic kidney disease | 21% | |
| Cancer | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, dobutamine hydrochloride, per 250 mg J1250 | Office | 11 | 11 | $71 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in California
Matthew Price
Interventional Cardiology · La Jolla, CA
Frederick St Goar
Interventional Cardiology · Mountain View, CA
Saibal Kar
Interventional Cardiology · Thousand Oaks, CA
Rahul Sharma
Interventional Cardiology · Stanford, CA
Puneet Khanna
Interventional Cardiology · Rancho Mirage, CA
Dennis Sheehan
Interventional Cardiology · Redwood City, CA
Related records
Interventional Cardiology in California
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.